<DOC>
	<DOCNO>NCT00410813</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This randomized phase II trial study two different schedule dasatinib compare well work treat patient stage IV breast cancer spread bone .</brief_summary>
	<brief_title>S0622 , Dasatinib Treating Patients With Stage IV Breast Cancer That Has Spread Bone</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free survival patient stage IV bone metastasis-predominant breast cancer treat 1 2 treatment schedule dasatinib . - Compare response rate ( complete partial , confirm unconfirmed ) patient treat regimen . - Compare MUC-1 antigen response rate ( CA 15-3 CA 27-29 ) patient treat regimen . - Compare circulate tumor cell response rate patient treat regimen . - Compare anti-osteoclast activity , measure change bone turnover marker , patient treat regimen . - Compare frequency severity toxicity regimens patient . - Compare pain profile patient explore change time . OUTLINE : This randomize , multicenter study . Patients stratify accord concurrent trastuzumab ( Herceptin® ) treatment ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral dasatinib daily . - Arm II : Patients receive oral dasatinib twice daily . In treatment arm , treatment continue least 24 week absence disease progression unacceptable toxicity . Blood sample acquire patient weekly week 1 , 4 , 8 , 16 , 24 . Samples analyze tumor marker , circulate tumor cell , bone marker . Patients complete self-reported brief pain inventory questionnaire baseline week 8 , 16 , 24 . After completion study treatment , patient follow every 3-6 month 2 year . PROJECTED ACCRUAL : A total 80 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast carcinoma meeting follow criterion : Stage IV disease Bone metastasispredominant disease , define presence ≥ 1 bone metastasis without nonbone ( visceral soft tissue ) disease number bone metastases least number measurable visceral target lesion Visceral disease cause reduction ECOG performance status allow Must meet 1 follow criterion : Measurable disease within past 28 day Nonmeasurable disease rise serum CA 153 , CA 2729 , CEA , CA125 document 2 consecutive measurement take ≥ 14 day apart recent measurement within past 42 day These measurement need consecutive , prior measurement could month year prior current measurement marker consider investigator reflect disease progression The second serum marker value must great institution 's upper limit normal show ≥ 20 % increase first measurement No symptomatic brain CNS metastases Prior CNS brain metastasis allow provide treated radiotherapy ≥ 8 week ago No pleural pericardial effusion Hormone receptor status know Estrogen receptor and/or progesterone receptorpositive disease must progress ≥ 1 hormonal therapy metastatic setting PATIENT CHARACTERISTICS : Male female Menopausal status specify Zubrod performance status 02 QTc &lt; 450 msec EKG Ejection fraction ≥ 50 % MUGA 2dimensional echocardiogram significant abnormality within past 12 week patient trastuzumab No active infection require systemic therapy No uncontrolled concurrent condition would preclude ability take oral medication , include follow : Nausea Vomiting Diarrhea Lack physical integrity upper gastrointestinal tract Malabsorption syndrome No clinically significant cardiac disease , include follow : Congestive heart failure Symptomatic coronary artery disease Cardiac arrhythmias well control Myocardial infarction within past 12 month No concurrent active malignancy Prior malignancy allow provided patient currently diseasefree Not pregnant nursing Fertile patient must use effective contraception 3 month completion study therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior RankL inhibitor therapy No 1 prior cytotoxic chemotherapy metastatic disease At least 3 week since prior chemotherapy recover At least 1 week since prior radiotherapy nonCNS disease recover At least 3 week since prior concurrent intravenous bisphosphates ( e.g. , zoledronate ) At least 7 day since prior concurrent antiplatelet agent , include following* : Anticoagulants ( e.g. , tirofiban , eptifibatide , ticlopidine ) Aspirin aspirincontaining combination Dipyridamole Epoprostenol Clopidogrel Cilostazol Abciximab NOTE : *Nonsteroidal antiinflammatory drug medically indicate plateletinhibiting medication allow At least 7 day since prior concurrent CYP3A4 inhibitor , include follow : HIV protease inhibitor ( e.g. , amprenavir , atazanavir , fosamprenavir , indinavir , nelfinavir , ritonavir ) Select antibiotic ( e.g. , ciprofloxacin , clarithromycin , doxycycline , enoxacin , isoniazid , telithromycin ) Azole antifungal ( e.g. , itraconazole , ketoconazole , miconazole , voriconazole ) Select anesthetic ( e.g. , ketamine , propofol ) Hypericum perforatum ( St. John 's wort ) Nefazodone Nicardipine Diclofenac Quinidine Imatinib mesylate At least 7 day since prior concurrent medication prolong QTc interval , include follow : Antiarrhythmic agent ( e.g. , quinidine , procainamide , disopyramide phosphate , amiodarone , sotalol hydrochloride , ibutilide , dofetilide ) Antipsychotic agent ( e.g. , chlorpromazine , mesoridazine , thioridazine , pimozide , haloperidol , droperidol ) Select antibiotic ( e.g. , erythromycin , clarithromycin , sparfloxacin , pentamidine ) Narcotic analgesic ( e.g. , levomethadyl , methadone , domperidone ) Calcium channel blocker ( e.g. , bepridil , lidoflazine ) Antimalarial agent ( e.g. , halofantrine , chloroquine ) Parasympathomimetic agent ( e.g. , cisapride ) Arsenic trioxide No concurrent antineoplastic therapy breast cancer , include follow : Radiotherapy Chemotherapy Immunotherapy Biologic therapy Hormonal therapy Gene therapy No concurrent grapefruit juice consumption No concurrent shortacting antacid agent within 2 hour dasatinib administration Concurrent trastuzumab ( Herceptin® ) therapy HER2 positive patient allow provided patient continuous trastuzumab ≥ 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>